---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-020025"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2023-05-30T23:59:59+00:00"
generated_at: "2026-06-14T11:45:42.695839+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics licenses CFT8919 to Betta Pharma for Greater China; receives $35M upfront/equity

## Summary
- $10M upfront cash + $25M equity investment from Betta affiliate at $4.49/share (10.2% ownership).
- Up to $357M in development/commercial milestones plus low-to-mid double-digit royalties on Greater China sales.
- C4T retains rights outside Greater China; eligible for low single-digit royalties on ex-China sales.
- CFT8919 is an oral BiDAC degrader targeting EGFR L858R NSCLC; IND submission to FDA expected H1 2023.
- Betta responsible for development/manufacturing/commercialization in licensed territories; C4T retains rest of world.

## SEC filing metadata
- accession: 0001628280-23-020025
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2023-05-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828023020025/0001628280-23-020025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828023020025/cccc-20230529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-020025
- JSON: https://secwatch.observer/filing/0001628280-23-020025.json
- Plain text: https://secwatch.observer/filing/0001628280-23-020025.txt

## Key facts
- Material Agreements
  C4 Therapeutics, Inc. entered into License Agreement with Betta Pharmaceuticals Co., Ltd. valued at upfront cash payment of $10.0 million and up to $357.0 million in aggregate milestone payments (effective 2023-05-29).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Betta Pharmaceuticals Co., Ltd.
  - Value: upfront cash payment of $10.0 million and up to $357.0 million in aggregate milestone payments
  - Effective: 2023-05-29
  source text: On May 29, 2023 , C4 Therapeutics, Inc. (“ C4T ”) entered into a License and Collaboration Agreement (“ License Agreement ”) with Betta Pharmaceuticals Co., Ltd. (“ Betta Pharma ”) to collaborate on the development and commercialization of CFT8919
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023020025/0001628280-23-020025-index.htm
- Material Agreements
  C4 Therapeutics, Inc. entered into Stock Purchase Agreement with Betta Pharmaceuticals Co., Ltd. and Betta Investment (Hong Kong) Limited valued at aggregate purchase price of approximately $25.0 million (effective 2023-05-29).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Betta Pharmaceuticals Co., Ltd. and Betta Investment (Hong Kong) Limited
  - Value: aggregate purchase price of approximately $25.0 million
  - Effective: 2023-05-29
  source text: On May 29, 2023 and in connection with the execution of the License Agreement, C4T, Betta Pharma, and Betta Investment (Hong Kong) Limited (“ Betta Investment ”), an affiliate of Betta Pharma, entered into a Stock Purchase Agreement (the “ Stock Purchase Agreement ” and together with the License Agreement, the “ Betta Agreements ”), pursuant to which Betta Investment agreed to purchase 5,567,928 shares of C4T common stock (the “ Shares ”) for an aggregate purchase price of approximately $25.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828023020025/0001628280-23-020025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.